WALTHAM, Mass., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the screening of the first patient in the pivotal Phase 3 clinical trial of MIN-101 (Study MIN-101C07) as monotherapy for negative symptoms in patients diagnosed with schizophrenia.
WALTHAM, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that the company has submitted a New Drug Application
WALTHAM, Mass. , Sept. 26, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, will hold a conference call and live audio webcast on October 1, 2019 ,
Breakfast meeting to be held on Friday, March 6, 2020 in New York WALTHAM, Mass. , Feb. 28, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat unmet medical needs of central
Call at 8:00 a.m. Eastern Time on Tuesday, March 31, 2020 WALTHAM, Mass. , March 24, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies addressing high unmet medical needs in the treatment of
WALTHAM, Mass. , March 15, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV), a biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will host a Key Opinion Leader (KOL) meeting on the topic of
Call scheduled for 8:30 a.m. Eastern Time on June 24 to review results of successful Phase 2b trial showing achievement of primary and secondary endpoints with potential first-in-class specific orexin- 2 receptor antagonist for the treatment of insomnia Key Opinion Leaders, Dr. Thomas Roth and Dr.
